OxyDial

About OxyDial

We have developed a next-generation blood testing instrument for measuring Oxygen-hemoglobin Dissociation Curve and MetHemoglobin - 10 times more precise, 3 times faster than current market devices, and requires only a drop of blood. We aim to radically streamline pharma R&D, Clinical, Chronic, and Emergency Medical Care, helping improve outcomes for patients suffering from blood disorders worldwide.

In addition to our focus on healthcare, we also target Military, Athletic & High-Altitude Training, Animal Testing & Research, Field Testing, and other markets.

Team

Olek Shestakov

Founder

Problem statement

The Oxygen-Hemoglobin Equilibrium Curve (OEC) is a fundamental measurement for understanding how a patient’s blood carries and releases oxygen. This test is critically important for establishing therapeutic processes for many disorders, like sickle cell anemia and pulmonary diseases.

Currently-available OEC blood testing devices have many shortcomings as a result of the lack of major development or advancement in the last two decades. They cannot support current market needs due to large blood sample requirements, complex supply chains, lengthy testing time, messy blood spills, frequent calibration and maintenance, and difficult operation.

Traction information

We are post-revenue ($96k in sales), our product is ready and in the process of FDA & EMA certification. Our foundational client is PFIZER, and we are in an extensive remote and on-site pilot program with them. We sell instruments/services for R&D purposes pre-FDA approval, and are actively expanding our referrals & pipeline.

Updates

Profile created.

Added over 1 year ago